Drug intelligence / Profile preview

TQA3605

Development stage: Phase 3
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

TQA3605 is an orally available small molecule drug under development for the treatment of chronic hepatitis B virus (HBV) infection. It acts as a capsid protein inhibitor, targeting the HBV core/capsid protein to disrupt viral replication. The drug is being developed by Chia Tai Tianqing Pharmaceutical Group and has reached Phase II clinical trials in China, both as monotherapy and in combination with nucleos(t)ide analogues. Its primary indication is chronic hepatitis B, where it aims to improve virological response rates compared to standard therapy[1][2][3].

Targets

HBc (Hepatitis B virus core protein)

Beyond the preview

Go deeper on TQA3605.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQA3605.

Explore the full profile